# A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

> **NCT01173497** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 44 (actual)

## Conditions studied

- Estrogen Receptor Negative (ER-Negative) Breast Cancer
- Progesterone Receptor Negative (PR-Negative) Breast Cancer
- Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer
- Brain Metastases

## Interventions

- **DRUG:** INIPARIB + irinotecan

## Key facts

- **NCT ID:** NCT01173497
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-10
- **Final completion:** 2013-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2016-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01173497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01173497, "A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01173497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*